Navigation Links
Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer
Date:6/30/2011

CAMBRIDGE, Mass., June 30, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that it will present preclinical data on MM-151, an oligoclonal therapeutic consisting of a mixture of three human antibody antagonists, and MM-398, a nanoliposomal encapsulation of irinotecan, at the 14th World Conference on Lung Cancer, taking place July 3 – 7, 2011, in Amsterdam, The Netherlands.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

MM-151MM-151 is designed to effectively block downstream signaling of the EGFR receptor, a key oncogene in various carcinomas. The poster will present pre-clinical data regarding the potency of MM-151 compared to existing monoclonal therapies targeting EGFR.Poster #3656 presents preclinical data on the ability of  MM-151 to effectively block EGFR pathway activation in in-vitro signaling and inhibit tumor cell growth in-vitro and in-vivo in lung cancer modelsPoster Session:  P2.070: Poster Session 2

Number:  3656

Date/Time:  Tuesday, July 5, from 12:15 PM – 2:00 PM

Location:  RAI Exhibition and Convention Centre, Exhibition HallMM-398  

MM-398 is designed to stably retain and protect irinotecan while in circulation in the body and enable efficient accumulation of the drug in solid tumors.  MM-398, in partnership with PharmaEngine, Inc., is in clinical development in colorectal, gastric and pancreatic cancer and in glioma.  The poster will present preclinical data on the safety and activity of MM-398 in lung cancer xenograft models.Poster #S420-421 presents preclinical data on MM-398's safety and activity Oral Session:  033.03: Preclinical Models 1

Number:  S420-421

Date/Time:  Wednesday, July 6, from 2:30 PM – 4:00 PM

Location:  Room D201About Merrimack Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer. Merrimack is advancing a pipeline of engineered therapeutics paired with molecular diagnostics. In addition to several pre-clinical and research-stage programs, Merrimack has five oncology candidates in clinical development or expected to enter clinical development this year: MM-398, in Phase 2 testing in partnership with PharmaEngine, Inc., MM-121, in Phase 2 testing in partnership with Sanofi, MM-111 in Phase 1 / 2 testing; and MM-302 and MM-151, which are both expected to enter Phase 1 clinical development this year. MM-398, MM-121, MM-111, MM-302 and MM-151 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. Merrimack uses its proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, to integrate the fields of engineering, biology and computing to enable mechanism-based model driven discovery and development of both therapeutic s and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.

Contact:  Rachel Yaroschuk, Corporate Communications, Merrimack, 617-441-7414  
Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
2. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
3. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
4. Co-Founder Gavin MacBeath, Ph.D. Joins Merrimack Pharmaceuticals as a Senior Director and the Head of Translational Research
5. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
6. Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR)
7. Clet Niyikiza, Merrimack's Executive Vice President of Development, to Present at BioVisionAlexandria 2010
8. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
9. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
10. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
11. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , ... October 11, 2017 , ... Disappearing forests and ... lives of over 5.5 million people each year. Especially those living in larger cities ... Treepex - based in one of the most pollution-affected countries globally - decided to ...
(Date:10/10/2017)... ... 10, 2017 , ... For the second time in three ... Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October ... US2020’s mission is to change the trajectory of STEM education in America by ...
(Date:10/10/2017)... PITTSBURGH, PA (PRWEB) , ... October 10, 2017 ... ... this year’s recipients of 13 prestigious awards honoring scientists who ... be presented in a scheduled symposium during Pittcon 2018, the world’s leading conference ...
(Date:10/9/2017)... Antonio, Texas (PRWEB) , ... ... ... new study published on October 5, 2017, in the medical journal, Epilepsia, ... equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic seizures ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
Breaking Biology News(10 mins):